BioFire Respiratory Panel with COVID Target Scores CE Mark
July 17, 2020
BioMerieux announced that Utah-based BioFire’s Respiratory Panel 2.1 plus, which tests for SARS-CoV-2 and 23 pathogens encompassing 19 viruses, and four bacteria that cause the most frequent respiratory tract infections, has received CE marking.
“It’s exciting to see the advances that BioFire is making in COVID-19 and infectious disease diagnostics,” said Kelvyn Cullimore, president and CEO of BioUtah. “And it’s happening right here in Utah.”
An earlier version of the test received EUA from the FDA in May. These panel tests, which are designed to detect and differentiate between SARS-CoV-2 and a number of other viral and bacterial respiratory pathogens, get results in about 45 minutes, and are part of a larger BioFire COVID-19 test menu. In March, the company was granted EUA for BioMerieux’s’ subsidiary BioFire Defense’s’ rapid COVID-19 assay, which has the same 45 minute runtime.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
